



**STATE BOARD OF EQUALIZATION
STAFF LEGISLATIVE BILL ANALYSIS**

Date Introduced:	02/14/01	Bill No:	AB 249
Tax:	Sales and Use	Author:	Matthews, et al.
Board Position:		Related Bills:	

BILL SUMMARY

This bill would codify the Board's regulation relating to the exemption for sales and purchases of lancets and blood glucose test strips furnished by a registered pharmacist for the treatment of diabetes.

ANALYSIS

Current Law

Under existing law, except where specifically exempted by statute, sales or use tax is imposed on all retailers for the privilege of selling tangible personal property at retail in this state. Section 6369 of the Sales and Use Tax Law provides that sales of medicine, when prescribed and sold or furnished under certain conditions for the treatment of a human being, are exempt from sales and use tax. Although an item, device, or apparatus may be prescribed by a physician for the treatment of a patient, for the sale to be exempt from tax, the item must qualify as a "medicine" under Section 6369.

Under this section, certain named devices, instruments, apparatus, devices, and physical equipment are included within the term "medicine" and therefore qualify for the exemption from tax. For example, the sale or use of insulin and insulin syringes furnished by a registered pharmacist for treatment of diabetes are specifically included within the term "medicine" and therefore currently qualify for an exemption from tax.

The Board's Regulation 1591.1, *Specific Medical Devices, Appliances, and Related Supplies*, interprets and makes specific the provisions of Section 6369. Under the regulation, sales and purchases of glucose test strips and skin puncture lancets furnished by a registered pharmacist that are used by a diabetic patient to determine his or her own blood sugar level and the necessity for and amount of insulin and/or other diabetic control medication needed to treat the disease in accordance with a physician's instructions are considered an integral and necessary active part of the use of insulin and insulin syringes and, accordingly, are not subject to sales or use tax. Sales and purchases of these items over-the-counter without being furnished by a registered pharmacist, however, remain subject to tax.

This staff analysis is provided to address various administrative, cost, revenue and policy issues; it is not to be construed to reflect or suggest the Board's formal position

Proposed Law

This bill would amend Section 6369 of the Sales and Use Tax Law to include within the term “medicines,” blood glucose strips and lancets furnished by a registered pharmacist to a person for the treatment of diabetes as directed by a physician.

The provisions of the bill would become operative on the first day of the first calendar quarter commencing more than 90 days of date the bill becomes enacted.

Background

Last year, during the 2000 Legislative Session, AB 2587 (Cardenas, et al.) was considered by the Legislature to 1) provide a sales and use tax exemption for the sale and purchase of blood glucose monitors whether or not the devices are furnished by a registered pharmacist, 2) codify the Board’s regulation relating to the exemption for sales and purchases of lancets and blood glucose test strips, and 3) expand the regulation by eliminating the requirement that these items be furnished by a registered pharmacist in order for the exemption to apply. That measure, which the Board voted to support, was held in the Assembly Appropriations Committee.

COMMENTS

1. **Sponsor and purpose of the bill.** According to the author’s office, the sponsor of this measure is the California Pharmacists Association. Its purpose is to codify the Board’s regulation concerning the application of sales and use tax to sales and purchases of blood glucose test strips and lancets furnished for the treatment of diabetes.
2. **This bill would not materially affect the Board’s administration of the Sales and Use Tax Law.** Since this bill would codify the Board’s interpretation of the law, it would not materially affect the Board’s workload.

COST ESTIMATE

Enactment of this bill would not materially affect the Board’s administrative costs.

REVENUE ESTIMATE

Since this bill would codify the Board’s regulation regarding the application of tax to blood glucose strips and lancets, the bill would not impact state or local revenues.

Analysis prepared by:	Sheila T. Sarem	445-6579	03/16/01
Contact:	Margaret S. Shedd	322-2376	
im			

This staff analysis is provided to address various administrative, cost, revenue and policy issues; it is not to be construed to reflect or suggest the Board’s formal position.